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Abstract
Transplantation carries significant mortality benefit compared to dialysis in 
end-stage kidney disease. Increased perioperative risk, however, results in a higher 
mortality in the first 3 months post-transplantation compared to remaining on hae-
modialysis. Consequently, optimal perioperative management is essential. Patients 
presenting for kidney transplantation require rapid assessment and preparation for 
theatre to minimise ischaemic times and improve mortality and graft outcomes. 
This task is often complicated by the presence of multiple medical comorbidities. 
Furthermore, early complications of hypotension, delayed graft function, reno-
vascular and ureteric surgical complications and rejection render the perioperative 
phase of transplant challenging for the recipient and for the transplant team. In this 
chapter, we outline current practices in the assessment and management of kidney 
transplant recipients during the perioperative period, particularly focusing on their 
clinical application and the evidence underpinning them.
Keywords: comorbidity, kidney transplantation, perioperative care,  
risk assessment, treatment outcome
1. Introduction
Non-communicable diseases now account for 75% of deaths globally, with 
chronic kidney disease (CKD) rapidly rising up the ranks as a cause of death, reach-
ing eleventh on the list in 2016 [1]. The estimated global crude prevalence of CKD in 
2016 was 275.9 million cases associated with a crude mortality of 1.2 million [2].
As CKD patients’ renal function declines, mortality rises to an estimated lifespan 
of 8 years for patients on dialysis of 40–44 years of age and 4.5 years to patients 
60–64 years of age. Improvements in dialysis therapy have been accompanied by 
a decline in mortality rate [3]. Despite this, the long-term mortality on dialysis 
remains significantly inferior to that following kidney transplantation.
A systematic review in 2011 identified 110 studies including nearly 2 million 
patients with transplantation conferring a mortality advantage over dialysis. Only 
studies with follow-up periods <3 months favoured dialysis, attributed largely to 
perioperative complications and higher immunosuppression post-transplantation 
[4]. Accordingly, transplant and dialysis registry studies have confirmed increased 
mortality in transplanted patients compared to dialysis at 3 months (HR 2.0, 1.5–2.7, 
p < 0.001) with reversal at 6 months (HR 0.27, 0.16–0.47, p < 0.001) with 80% 
reduction in mortality following transplantation compared to dialysis at 12 months [5]. 
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The increase in mortality associated with kidney transplantation highlights the 
need for optimal perioperative management to minimise the risks and maximise the 
benefits associated with transplantation. This chapter focuses on the principles and 
evidence of perioperative management of transplant patients.
2. Pre-operative transplant management
2.1 Initial clinical assessment pre-transplant
Patients on the kidney transplant waiting list have usually undergone a thorough 
medical and surgical assessment prior to listing to identify significant comorbidities 
that would preclude transplantation. Optimisation of cardiovascular comorbidi-
ties, including diabetes mellitus (DM) and hypertension, is important not only for 
prevention of cardiovascular disease but also for avoidance of hypertensive and dia-
betic damage to the transplanted graft. Nevertheless, at the point that an intended 
recipient is admitted to hospital for transplantation, a thorough reassessment is 
important to identify any new medical issues, as well as to ensure that the recipient 
is sufficiently medically stable for a general anaesthetic and surgery.
On arrival at the transplanting hospital, bloods are collected with a request for 
the laboratory to process these urgently (Table 1). In addition, a chest radiograph 
and ECG are performed.
While these investigations are being processed, a medical history and examina-
tion should be undertaken with the patient with the aim of documenting:
• Any new medical comorbidities, in particular symptoms suggesting the 
development of vascular disease (angina, claudication, peripheral ulceration), 
malignancy (unexpected weight loss, new mass or lymphadenopathy) or active 
infection (fever, constitutional symptoms).
• Signs or symptoms of fluid overload, with assessment of the patient’s weight in 
relation to their recent clinic weights (or current target weight if on dialysis).
• The patient’s usual daily urine volume.
The presence of potential new medical comorbidities should prompt review of 
suitability for, and safety of proceeding with transplantation. The development 
of ischaemic heart disease, vascular disease, malignancy or active infection would 
preclude proceeding with transplantation.
Blood tests:
Renal and liver chemistry including phosphate, calcium, and LDH
Full blood count
Coagulation profile
Blood group + hold
Serum for tissue typing investigations
Serology for CMV, EBV, VZV, toxoplasma hepatitis B, hepatitis C, HIV
Pregnancy test as appropriate
Urine culture unless anuric
Chest radiograph
Electrocardiogram
Table 1. 
Usual investigations for a patient presenting for kidney transplant.
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A key decision during the assessment is whether a patient requires dialysis 
prior to transplantation. Similarly, donor factors associated with a high prob-
ability of delayed graft function (e.g., donation after circulatory death [DCD] 
kidney, prolonged anticipated cold ischaemic time) require a lower threshold for 
dialysis. Significant hyperkalaemia (a typical threshold may be a serum potassium 
concentration > 5.5 mmol/L) or fluid overload should prompt urgent dialysis prior 
to transplantation. In general, it is better to control fluid and electrolyte abnormali-
ties effectively with dialysis pre-operatively rather than to attempt dialysis in a 
less stable patient post-surgery. Due to tissue damage and intraoperative bleeding, 
hyperkalaemia may worsen post-operatively. If haemodialysis is required prior to 
transplantation, patients are usually slightly above their target weight with the aim 
of avoiding intraoperative hypotension. Minimal or no heparin should be adminis-
tered during dialysis to minimise the risk of perioperative haemorrhage.
2.2 Management of pre-existing medication
Patients with advanced kidney disease are often on multiple medications, many 
of which can be safely discontinued at the time of transplantation, including most 
antihypertensive medication, phosphate binders, cinacalcet, and erythropoiesis-
stimulating agents. However, some medications should usually be continued as 
follows:
• Active vitamin D compounds in patients post-parathyroidectomy are usually 
continued. Calcium levels post-transplant follow a biphasic pattern with early 
decline in the post-operative week without supplementation. The protective 
effect of raised PTH is absent in patients post-parathyroidectomy, thereby 
risking precipitating severe hypocalcaemia if such patients are not supple-
mented with active vitamin D compounds (calcitriol and alfacalcidol) [6].
• Beta blockers are usually not stopped abruptly in the perioperative period due 
to concerns that this may lead to rebound tachycardia and increase the risk of 
mortality [7]. However, it may be reasonable to reduce the dose and/or convert 
patients to a beta blocker with a shorter duration of action (e.g., metoprolol) to 
reduce the risk of hypotension in the post-operative period.
• Statins, although generally safe, can predispose to rhabdomyolysis if used in 
conjunction with CYP450-3A4 inhibitors [8]. We suggest ceasing statins until 
outside the perioperative period.
• Antiplatelet therapy with aspirin is usually continued perioperatively, and 
many transplant centres routinely prescribe aspirin to recipients who are not 
already receiving this agent to reduce the risk of transplant vessel throm-
bosis, although this has a poor evidence base [9]. Dual antiplatelet therapy 
with aspirin plus agents, such as platelet P2Y12 receptor inhibitors (e.g., 
clopidogrel and ticagrelor), would usually be considered a contraindication 
to transplantation, both because of the increased risk of bleeding and the 
frequent association of significant vascular disease in patients requiring this 
combination.
• Erythropoiesis stimulating agents (ESA) may be continued on the basis of 
some studies identifying anaemia as an independent predictor of mortality in 
the intermediate post-transplant period [10]. There are, however, no studies 
showing benefits of continued ESA therapy or defining optimal haemoglobin 
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targets [11]. European Best Practices Guidelines for anaemia management 
recommend that ESA not be ceased in patients undergoing surgery, but no 
specific recommendations are made regarding transplantation [12].
Potential transplant recipients who are anti-coagulated with warfarin require 
urgent reversal of anticoagulation prior to surgery. There are often local proto-
cols for warfarin reversal, but a typical approach would be 1–2 mg oral vitamin 
K administered as soon as the patient presents to hospital, followed by infusion 
of either fresh frozen plasma or a prothrombin complex concentrate, such as 
prothrombinex-VF, depending on the INR [13]. Whether intravenous heparin is 
required post-operatively will depend on the strength of the indication for anti-
coagulation, the degree of post-operative haemorrhage, and a decision regarding 
this should be made in consultation with the transplant surgeons. Where the risk of 
thrombosis is not excessively high, it is preferable to defer recommencing warfarin 
until at least 4 weeks post-transplant due to the frequent requirement for a trans-
plant biopsy during this period.
Although non-vitamin K oral anticoagulants (NOACs) are currently not used 
routinely in end-stage kidney disease (ESKD) patients, indications for their use 
have been expanding into patients with more severe renal dysfunction. Nonetheless, 
NOACs should be avoided in ESKD patients on the active transplant list.
2.3 Pre-operative management of diabetes and hyperglycaemia
In Australia, over 23% of patients who are listed for a deceased donor transplant 
have diabetes [ANZDATA 2016]. The presence of autonomic neuropathy should 
be noted, as this may help predict haemodynamic instability and risk for graft 
hypoperfusion post-operatively. Similarly, gastroparesis may have important 
implications for immunosuppressive drug absorption if severe and retinopathy may 
complicate post-operative medication management if visual acuity is substantially 
reduced.
After admission for kidney transplantation, patients with type 2 diabetes should 
omit hypoglycaemic medication during the period of preoperative fasting, with 
regular capillary glucose monitoring performed every 1–2 h. Hypoglycaemia is 
managed with intravenous dextrose. If significant hyperglycaemia develops, an 
intravenous insulin infusion is the safest method to control glucose levels until the 
recipient is able to eat post-operatively. Patients with type 1 diabetes should com-
mence an intravenous insulin infusion after admission to hospital to prevent the 
development of ketoacidosis.
2.4 Immunosuppression
After the decision has been made to proceed with a transplant, an immunosup-
pression regimen is selected. This regimen is usually initiated before the recipient 
goes to theatre so that immune function is attenuated prior to donor antigen expo-
sure after reperfusion of the allograft. The choice of immunosuppressive regimen is 
individualised depending on the circumstances of the recipient and, in particular, 
the perception of immunological risk (Table 2).
Most patients undergoing kidney transplantation will receive induction immu-
nosuppression, typically consisting of intravenous methylprednisolone combined 
with either a monoclonal antibody targeting CD25 (the high affinity α-chain of the 
IL-2 receptor) [14], such as basiliximab, or a lymphocyte-depleting antibody (such 
as thymoglobulin [15] or alemtuzumab [16–18]). Induction therapy is combined 
with ongoing maintenance immunosuppressive therapy, typically consisting of 
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three immunosuppressive agents [19]. The most commonly prescribed combination 
in Australia and the USA currently is tacrolimus, mycophenolate and prednisolone 
[20, 21]. ABO-incompatible transplants as well transplants where there is a pre-
transplant DSA requiring plasma-exchange prior to transplantation are outside 
the scope of this chapter. Similarly, special circumstances including steroid-free 
immunosuppression are not discussed here.
2.5 Prophylactic medications
The administration of immunosuppression needs to be balanced against the 
increased risk of infection. With ESKD patients being routinely subjected to 
hospital environments, additional consideration should be given for prophylaxis 
in patients colonised with multi-resistant organisms. Patients with prior known 
serious or recurrent infections should be evaluated carefully and assessed for 
recurrence and presence of occult infection prior to proceeding with transplanta-
tion. In addition, gastro-protection, infection and VTE prophylaxis is charted 
(Table 3).
Despite some controversy for the use of surgical antibiotic prophylaxis, rou-
tine prescribing is common, generally following local practices and guidelines 
[22]. No consensus currently exists for optimal antibacterial prophylaxis, but the 
general approach is to minimise dose and duration of administration to prevent 
emergence of antibiotic resistance [23]. A Cochrane systematic review is currently 
being undertaken to evaluate the evidence for antibiotic prophylaxis in preventing 
postsurgical site infections in solid organ transplant recipients [24]. Where there 
are risk factors that may predispose the recipient to bacterial transmission from 
the donor, such as treated bacteraemia or urine infection, the duration of antibiotic 
prophylaxis is adapted to cover the appropriate organisms.
Prior to introduction of prophylaxis, PJP was an important cause of severe 
pneumonia, associated with an estimated 29–50% mortality [25]. Since the wide-
spread use of co-trimoxazole prophylaxis, the incidence of PJP has declined to an 
estimated incidence of 0.8 case per 1000 person at 1-year post-transplant [26]. 
Co-trimoxazole prophylaxis is routinely prescribed in most transplant centres for 
6–12 months post-transplant and many centres now advocate for continued prophy-
laxis following PJP outbreaks [27]. If co-trimoxazole is contraindicated, alternative 
agents are inhaled pentamidine isethionate or oral dapsone.
Prophylaxis against urinary tract infections (UTIs) is usually provided by the 
co-trimoxazole therapy administered for PJP prophylaxis. On the basis of limited 
evidence, perioperative UTI prophylaxis is recommended and in the case of co-
trimoxazole intolerance, another agent could be chosen [11].
Systemic anti-fungal prophylaxis is not routinely administered to kidney 
transplant recipients [28]. However, oral nystatin or amphotericin is frequently 
Very low risk Identical twin donor
Low risk HLA-identical sibling donor, no DSA
Average risk HLA-mismatched donor, no DSA
High risk HLA-mismatched donor, detectable DSA, negative cross-match or  
ABO-incompatible donor following desensitisation
Very high risk HLA-mismatched donor, detectable DSA, positive cross-match
DSA, donor-specific antibody.
Table 2. 
Immunological risk assessment for kidney transplantation.
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prescribed in the early post-operative period to reduce the risk of oropharyngeal 
candida infection [11]. The optimal duration of therapy is unknown, largely due to 
low event rates, but a typical approach would be therapy for the first month post-
transplant [29].
Previous cytomegalovirus (CMV) infection is common, with a seroprevalence 
of up to 75% in transplant recipients [30]. The risk of developing CMV viraemia 
post-transplant depends on the serostatus of both donor and recipient as well as the 
induction immunosuppression agent (Table 4). The highest risk CMV infection 
is seen in seronegative recipients of a transplant from a seropositive donor, and is 
increased in patients treated with T cell depleting agents [31].
Several antiviral agents have been shown to reduce the risk of CMV infection 
(with the added benefit of also providing prophylaxis against herpes simplex 
and herpes zoster reactivation) in transplant recipients, including intravenous 
ganciclovir and oral acyclovir and valganciclovir, irrespective of donor status and 
induction immunosuppressive regimen [32]. Unfortunately, viral prophylaxis has 
shown little benefit in reducing the incidence of EBV-related PTLD [33]. Sustained 
prophylaxis benefit is observed with longer duration therapy (>3 months) with 
the main adverse effects being leukopenia with longer therapy duration [32]. 
Due to the observed benefit in reducing the incidence of CMV disease and cost 
effectiveness, 6 months antiviral prophylaxis is generally prescribed in high-risk 
CMV D+R− pairs [34]. An accepted alternative approach to universal prophylaxis 
is to monitor for CMV viraemia regularly post-transplant and initiate pre-emptive 
therapy should significant viraemia develop [32, 35].
Due to the gastro-erosive effects of prednisolone, ranitidine 150 mg twice daily 
for gastro-protection is usually recommended, noting the potential risk of interstitial 
nephritis and chronic kidney disease with proton-pump inhibitors (PPIs) [36, 37].  
If ranitidine is contraindicated or ineffective, use of low dose PPIs as second line is 
recommended.
Deep venous thrombosis (DVT) has not been extensively evaluated in the 
literature. Kidney transplantation is categorised as a moderate risk group of patients 
for development of thromboprophylaxis conferring an estimated risk of DVT of 
6% [38]. Limited studies have suggested the incidence to be lower with mechanical 
thromboprophylaxis alone [39]. Despite the lack of evidence, thromboprophylaxis 
Gastro-protection Ranitidine (or PPI) therapy while on high dose steroids
Bacterial prophylaxis Perioperative antibiotic therapy prescribed based on local guidelines and 
adapted for recipient multi-resistant organism colonization or potential 
donor infection
PJP prophylaxis 6–12 months co-trimoxazole. Consider lifelong therapy
UTI prophylaxis 6 months co-trimoxazole
Oropharyngeal candidiasis 
prophylaxis
Oral nystatin or amphotericin for duration of admission. Optimal duration 
uncertain
Systemic fungal 
prophylaxis
Not generally prescribed due to low incidence of invasive fungal infection
CMV prophylaxis Oral valganciclovir. Duration depending on donor and recipient serostatus—
see Table 4
VTE prophylaxis Unfractionated heparin and mechanical calf compressors unless 
contraindicated until patient mobile
Table 3. 
Perioperative prophylaxis.
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is generally initiated immediately post-operatively in the absence of contraindica-
tions or concerns of active haemorrhage. A combination of unfractionated heparin 
prophylaxis and mechanical calf compression is used, following local guidelines.
3. Intra-operative and immediate post-operative considerations
Although surgical and anaesthetic approaches and considerations are outside the 
scope of this chapter, intra-operative events have significant impacts on patient and 
graft outcomes. Review and documentation of intra-operative and immediate post-
operative factors can help predict and guide subsequent clinical course (Table 5).
Any surgical complications or anatomical challenges (notably presence of 
multiple renal arteries, difficult bench surgery and renal capsule tear) should be 
communicated by the transplant surgeons as these can help predict perioperative 
complications. If available, intraoperative Doppler assessments should be docu-
mented to confirm adequate post-perfusion flow parameters in the transplanted 
kidney. Where there is perioperative concern regarding allograft perfusion, or early 
unexpected oligoanuria, an early duplex ultrasound may be requested to confirm 
flow in the transplant vessels.
Significant blood loss, requirement of inotropic support and intra-operative 
haemodynamic instability indicate suboptimal organ perfusion and are risk factors 
for delayed graft function (Section 5.4). Central venous line is placed at the time of 
surgery, and central venous pressure (CVP) is still used intra-operatively and in the 
immediate post-operative period. It is important to acknowledge controversies in 
absolute CVP targets, with studies advocating improved outcomes with high CVP 
(10–15 mmHg) targets at reperfusion [40, 41] and others observing increased kid-
ney dysfunction with CVP >11 mmHg [42]. In general, intra-operative CVP trends 
can inform fluid management, but should not form the basis of a fluid management 
strategy due to inconsistent correlation with intravascular volumes [43].
Despite preoperative optimization, hyperkalaemia is common post-operatively 
due to tissue trauma and resorption of intra-abdominal blood. The presence of 
CMV D−R− Usually no prophylaxis
CMV D+R+ or D−R+ Valganciclovir for 3 months
CMV D+R− Valganciclovir for 6 months
D, donor serostatus; R, recipient serostatus.
Table 4. 
Prophylaxis for cytomegalovirus.
Donor graft Graft anatomy, backbench surgery, renal capsule tear
Graft perfusion Appearance on cross-clamp release. Intraoperative Dopplers
Haemodynamics Blood pressure profile, CVP, need for inotropic support, blood loss volume
Fluid balance Volume of intravenous fluid administration during procedure, urine output
Biochemistry Intraoperative insulin dextrose. Post-operative renal chemistry panel including urea, 
creatinine and potassium
Assessment of listed factors helps guide and predict perioperative management
Table 5. 
Post-operative documentation.
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hyperkalaemia >6 mmol/L in the immediate post-operative period should prompt 
consideration of dialysis depending on the urine output. If graft urine output (with 
native residual renal function deducted) is >100 mL/h, it may be reasonable to 
manage the patient medically with insulin-dextrose infusion and loop diuretics. 
It should also be noted that intraoperative use of insulin-dextrose often results in 
rebound hyperkalaemia postoperatively.
4. Perioperative fluid management
Optimal fluid management strategy is contentious, although there is good 
evidence that fluid loading to maintain cardiac output and optimise renal perfu-
sion, improves outcomes [44]. Intra-operative blood losses and fluid balance can 
be estimated through discussion with the transplant surgeon and anaesthetist and 
review of anaesthetic chart (Section 3). Currently, no studies on fluid manage-
ment in the perioperative phase of renal transplantation exist to guide practice. 
A recent randomised trial demonstrated non-inferiority of a non-restrictive 
perioperative intravenous fluid strategy in high-risk abdominal surgery in terms 
of disability-free survival. Furthermore, the restrictive fluid strategy was associ-
ated with increased rates of acute kidney injury (8.6 vs. 5.0%. p < 0.001) [45]. 
Although generalizability to renal transplantation is uncertain, a restrictive fluid 
strategy should be avoided.
A common strategy for managing post-operative fluid replacement in the hours 
after kidney transplantation is to replace the urine output from the previous hour 
plus 30 mL to account for insensible losses. A loop diuretic and/or mannitol is 
sometimes administered during the transplant surgery to precipitate a diuresis, 
decreasing requirement for dialysis, but has not been shown to improve graft 
outcomes [46].
Frequent clinical assessment of the recipient’s fluid status, including the jugular 
venous pressure, heart rate, blood pressure and urine output, is important to ensure 
adequate fluid replacement and to avoid volume overload. Traditional parameters 
and clinical assessment of fluid status, however, may be unreliable due to com-
promised homeostatic mechanisms in ESKD and the post-ischaemic transplanted 
kidney [47]. As soon as it is feasible post-transplant, recipients should be weighed 
with comparison to their preoperative weight as an objective guide to fluid status.
There is currently no evidence supporting one type of intravenous fluid 
therapy over another, although a pragmatic, registry-based, multi-centre, double-
blind, randomised controlled trial comparing balanced crystalloid solution 
(PlasmaLyte) with 0.9% saline on the incidence of delayed graft function in 800 
adults and children with end-stage kidney disease (ESKD) receiving a deceased 
donor kidney transplant in Australia and New Zealand is currently underway 
(ACTRN12617000358347).
A good urine output in the early post-transplant period is a helpful indicator of 
early graft function, although it may not be possible to differentiate allograft urine 
output from native urine output in recipients who have significant residual renal 
function. Oligoanuria may be an indicator of delayed graft function or a harbinger 
of an early complication, especially if the urine output was good initially (Section 
5.4). An urgent ultrasound is a useful investigation to assess perfusion of the 
allograft at the bedside and to check for evidence of ureteric or vascular complica-
tions. The presence of hypoechoic fluid collections may indicate haemorrhage or 
urinary anastomotic leak (Section 5).
Blood tests to monitor serum creatinine and electrolytes are collected imme-
diately post-transplant and then 6–12 h to monitor renal function and exclude 
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hyperkalaemia. Some recipients may develop a significant diuresis, passing over a 
litre of urine per hour, and in this situation, frequent monitoring of blood tests 4–6 
h is recommended to avoid over or under replacement of electrolytes.
5. Early complications
Complications in the perioperative phase are diverse, reflecting pre-existing 
transplant recipient comorbidities as well as individual surgical challenges. With the 
potential for there to be few symptoms from the denervated graft, most centres fol-
low a protocol of investigations for early identification of post-transplant complica-
tions (Table 6).
Generally, an early renal transplant duplex ultrasound can identify vascular 
or anastomotic complications including renal vessel thrombosis or compression. 
The resistive index (RI) (measured peak systolic velocity—end diastolic velocity/
peak systolic velocity), normally, between 0.60 and 0.80, with levels >0.8 suggest-
ing abnormal perfusion of the allograft, is a widely reported measure of allograft 
perfusion for duplex scans but does not seem to correlate well with renal histology 
[48]. A positive correlation has been reported between RI and recipient mortality, 
and the strongest predictor of an elevated RI was recipient age, suggesting that RI 
may be an indicator of recipient vascular disease [48]. Consequently, although the 
RI is commonly reported, clinicians need to be aware of its limitations.
Similarly, nuclear medicine imaging, such as a mercaptoacetyltriglycine (MAG3) 
or diethylenetriamine pentaacetic acid (DTPA) renogram, can assist in the assess-
ment of allograft perfusion and early graft function as well as identify a ureteric 
anastomotic leak. Radionucleotide scanning may give an indication of the likely 
duration of delayed graft function [49, 50].
5.1 Haematological, biochemical and metabolic derangement
Electrolyte abnormalities are a frequent occurrence in the early post-transplant 
period. Perioperative hyperkalaemia is often followed by hypokalaemia due 
to diuretics and polyuria combined with large volume IV fluid replacement. 
Hypomagnesaemia is exacerbated by the tubular effects of CNI therapy and is asso-
ciated with an increased risk of post-transplant diabetes [51, 52]. Hypophosphatemia 
is almost universal as a consequence of elevated FGF23 and PTH levels [53, 54]. 
To reduce the chance of arrhythmias, intravenous electrolyte replacement should 
target potassium levels in the normal range (3.5–5 mmol/L) and a serum magnesium 
>0.4 mmol/L. Hypophosphatemia is not usually associated with adverse clinical 
sequelae, but if severe (<0.4 mmol/L) can also be managed with intravenous replace-
ment. Many transplant recipients require ongoing oral replacement of potassium, 
magnesium and occasionally phosphate in the first few weeks post-transplant, 
although this may be limited by gastrointestinal adverse effects.
Blood tests:
Twice daily full blood count and serum biochemistry
Alternate day CNI levels
Daily capillary glucose levels—if abnormal, manage as diabetes mellitus
Post-operative chest radiograph
Duplex ultrasound imaging, usually at days 2–4 post-transplant
MAG3/DTPA renogram as indicated by clinical progress
Table 6. 
Common post-operative surveillance investigations.
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Myelosuppression is commonly observed in post-transplant patients receiv-
ing immunosuppressive therapy. Myeloid, lymphoid and erythroid lineages can 
separately be affected in combination. Investigations focus on identification of the 
underlying cause for the haematological abnormality, and blood films are often 
helpful.
Post-operative anaemia is observed in around 40% of kidney transplant recipi-
ents due to erythropoietin deficiency, pre-transplant anaemia and intra-operative 
blood loss [55]. Initial management should focus ruling out haemorrhage as dis-
cussed in Section 5.2. The administration of an erythropoiesis-stimulating agent 
may be appropriate in recipients with poor initial graft function [11].
Lymphopenia and neutropenia are also common after transplantation, typically 
as a consequence of the medication-related bone marrow suppression associated 
with anti-proliferative agents (mycophenolate and azathioprine), mTOR inhibitors 
(sirolimus and everolimus) and antiviral agents such as valganciclovir for CMV pro-
phylaxis [56–58]. G-CSF is typically administered if the absolute neutrophil count 
falls below 1000/μL (1.0 × 109/L) to try to avoid a severe neutropenia (neutrophil 
count <500/μL, or < 0.5 × 109/L), which is associated with a significant risk of severe 
infections and requires reverse barrier nursing [59]. Alternative causes of neutrope-
nia should also be considered including parvovirus B12 and CMV infection [60].
Thrombocytopenia is comparatively less common, often occurring in conjunc-
tion with leukopenia due to bone marrow suppression as previously discussed. More 
severe thrombocytopenia is a risk factor for bleeding, and platelet transfusion may 
be necessary if invasive procedures, such as a renal biopsy, are required and the 
platelet count is <50 × 109/L [61]. An important consideration, if thrombocytopenia 
is observed post-transplant, is to look for any other evidence of thrombotic micro-
angiopathy (TMA, Table 7) [62]. TMA occurring after transplant may be due to 
recurrence of primary haemolytic uraemic syndrome, or a de novo problem. Many 
triggers for de novo TMA post-transplant have been reported, including medication 
(CNI therapy, particularly in combination with mTOR inhibitors; valacyclovir), 
and infections (CMV, parvovirus B19) have all been associated with TMA with the 
potential for graft damage and kidney injury [63–65].
The post-operative stress response, combined with induction corticosteroid and 
cyclosporine or tacrolimus therapy, can result in significant perioperative hyper-
glycaemia even in patients who do not have pre-existing diabetes, with a reported 
incidence as high as 80–90% in some studies [67, 68] with post-transplant diabetes 
persisting in 10–45% depending on the definition used [69–73]. Hyperglycaemia is 
also associated with rejection in the perioperative period and in the long term car-
ries adverse metabolic outcomes [74]. It is, therefore, important to monitor capillary 
glucose levels in all patients after kidney transplantation. Due to the contributions 
of immunosuppressive medications, and depending on other metabolic risk factors 
(pre-existing impaired glucose tolerance or diabetes, ethnicity, age and obesity) 
• Thrombocytopenia—platelet count <150 × 109/L
• Microangiopathic haemolytic anaemia (MAHA)—haemoglobin <10 g/dL with evidence of red cell frag-
ments on blood film (schistocytes)
• Elevated lactate dehydrogenase
• Elevated reticulocyte count
• Elevated bilirubin
• Reduced haptoglobin
Table 7. 
Features of thrombotic microangiopathy on laboratory tests [66].
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and immune risk, immunotherapy should be individualised [11]. A detailed discus-
sion of the management of post-transplant hyperglycaemia and diabetes is beyond 
the scope of this chapter.
5.2 Hypotension: haemorrhage, sepsis and cardiac dysfunction
Perioperative hypotension is common and may reflect inadequate intravascular 
volume, vasoplegia induced by anaesthetic or analgaesic agents or cardiac dysfunc-
tion. Management involves perioperative fluid status optimization with judicious 
administration of fluid boluses while excluding alternative causes of hypotension 
including haemorrhage, sepsis and cardiac dysfunction. Recipients with persistent 
hypotension, despite what appears to be adequate fluid replacement, may require 
temporary inotropic support. Hypovolaemia, even in the absence of hypotension, 
increases the risk of delayed graft function resulting in worse graft outcomes 
[75, 76]. As coronary artery disease is common in patients with ESKD, ruling out 
ischaemic myocardial damage with ECG review and cardiac enzyme assay measure-
ments is essential (Section 5.3).
Haemorrhage is common in the early period of kidney transplantation, frequently 
occurring within 48 h of surgery with a reported incidence of 15% [77]. Apart from 
hypotension, bleeding may manifest clinically with increasing surgical drain output, 
pain or swelling at the site of the transplant or a falling haemoglobin on serial blood 
tests. Risk factors for perioperative bleeding include difficult bench surgery, uraemic 
platelet dysfunction and administration of antiplatelet agents or heparin (either as 
thromboprophylaxis or during haemodialysis). In a retrospective analysis, difficult 
bench surgery was identified as the most significant risk factor for post-operative 
haemorrhage with a 4-fold increased risk. The use of antiplatelet drugs pre-transplant 
conferred a 2-fold increased risk. Additionally, dialysis vintage was also a risk factor, 
and each year on dialysis was associated with a 2% increased bleeding risk [77].
In the early post-operative phase, clinical features suggestive of haemorrhage 
should prompt urgent review of haematology profile, and consideration of imaging 
in liaison with the transplant surgeon. Peri-nephric hematomas may be identified 
on ultrasound, but deep or retroperitoneal haemorrhage may be difficult to identify 
requiring computed tomography. The development of a peri-nephric haematoma 
may lead to allograft compression, which if significant, may impair graft perfusion 
with increased diastolic pressures despite normal, or near normal, arcuate artery 
blood flow indices.
Management of perioperative bleeding requires administration of crystalloid fluids 
together with judicious transfusion of packed red cells to maintain adequate haemody-
namic and haemoglobin targets. Transfusions should be minimised as much as possi-
ble, as perioperative blood transfusion leads to recipient sensitization and can increase 
the likelihood of de novo DSA formation [78]. The decision to proceed to surgical 
drainage should be individualised, following discussion with the transplant surgeon. 
The presence of a large haematoma, ongoing haemodynamic instability or features 
suggesting compression of the allograft, would usually lead to surgical re-exploration.
Sepsis should also be considered in the setting of unexplained hypotension. 
A high index of suspicion for infection should be maintained at all times since 
transplant recipients may not develop a fever, leukocytosis or raised inflammatory 
markers because of their immunosuppressed state (Section 5.7).
5.3 Cardiovascular complications
Due to the significant cardiovascular disease burden and risk associated with 
chronic kidney disease, cardiovascular complications post-renal transplantation are 
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common. In a retrospective cohort study, the most common perioperative cardio-
vascular complication was arrhythmia (53%), followed by myocardial infarction 
(26.4%) with congestive heart failure being relatively rare (1%) [79, 80].
Hypertension, although often overlooked as a perioperative complication, is 
common, occurring in 50–70% of recipients. It is likely driven by multiple factors 
including pre-existing hypertension associated with ESKD, cessation of previous 
antihypertensive therapy at the time of transplantation, iatrogenic fluid admin-
istration to optimise allograft perfusion, calcineurin inhibitor therapy (CNI) and 
corticosteroid-related fluid retention [81]. Modification of fluid status, diuretic 
therapy and administration of dihydropyridine calcium channel blockers are 
common initial strategies used to control BP in the early post-transplant period. 
The non-dihydropyridine agents (diltiazem and verapamil) may be used, but have 
significant interactions with CNI (cyclosporine > tacrolimus) increasing CNI expo-
sure. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers 
are usually avoided in the perioperative period to due to their potential to increase 
creatinine levels but can be introduced once allograft function has stabilised with 
appropriate monitoring of creatinine and potassium levels.
Despite pre-transplant screening for ischaemic heart disease, acute coronary 
syndromes (ACS) are still seen in the peri-transplant period, an indication of the 
limited sensitivity of non-invasive cardiac testing to detect clinically significant 
coronary disease in the ESKD population [82, 83]. ACS are a difficult complication 
to manage in the perioperative setting due to competing clinical priorities, and the 
potential benefits of antiplatelet and anticoagulant therapy need to be balanced 
against the risk of bleeding. Evaluation of the impact of the infarct on ventricular 
function can be assessed by echocardiography. Decisions on the optimal manage-
ment including the potential need for angiography should be discussed with the 
local cardiology team.
Pre-existing congestive cardiac failure should be identified pre-transplantation 
and optimised through high-quality dialysis to control uraemia and volume 
overload as well as medical therapy. Large fluctuations in blood pressure and 
inter-dialytic weight gain will adversely affect myocardial function through car-
diomyopathic remodelling and vasoactive humoral-mediated increases in vascular 
tone and damage. It is important to acknowledge controversies surrounding optimal 
blood pressure targets in dialysis patients and to individualise both blood pressure 
target and pharmacological hypertensive therapy [84, 85].
5.4 Delayed graft function
Delayed graft function (DGF) is a form of acute kidney injury and is usually 
defined as the need for dialysis post-transplant. DGF is associated with a higher 
incidence of acute rejection as well as poorer allograft survival, with a reported 
40% greater risk of allograft loss and higher mean serum creatinine concentration 
[86, 87]. The reported frequency varies significantly (from 2 to 50%) due to hetero-
geneity of recipient and donor factors and definition of the event [75]. In Australia 
and New Zealand, nephrologist reported DGF is present in 19.5% of cadaveric renal 
transplants [ANZDATA 1997–2014].
Post-operative oliguria, failure of improvement of serum creatinine or the 
need for dialysis should prompt investigations to identify reversible causes of 
acute kidney injury, including assessment of risk factors for ATN, recipient 
hypotension or hypovolaemia, presence of post-surgical vascular or urological 
complications and rejection. In addition to a review of fluid status, haemody-
namic parameters and the timing of a decrease in urine output, the following 
testing should be considered:
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• Repeat serum biochemistry and haematology profile to rule out pre-renal 
kidney injury from anaemia and sepsis, taking account of haemoglobin and 
haematocrit fluctuations with fluid status dilution and unpredictable inflam-
matory response in the context of immunosuppression.
• Repeat CNI trough levels and review of CNI dosing and trends. These are 
nephrotoxic and may necessitate adjustment depending on the immune risk of 
the transplanted patient.
• Ultrasound duplex scan to rule out renovascular pathology. This also allows 
exclusion of peri-nephric collections and obstructive uropathy.
• Functional nuclear medical imaging, such as a MAG3, scan will allow assess-
ment of perfusion, graft tracer uptake, and excretion.
• A renal biopsy is usually undertaken if DGF persists at day 5 post-transplant 
to rule out rejection, and is repeated weekly until there are signs of improving 
allograft function.
It is also helpful to consider risk factors associated with DGF in order to risk 
stratify and anticipate the clinical course of the transplanted patient (Table 8) [75].
In the setting of DGF, ongoing dialysis is often required. In haemodialysis 
patients, every effort should be made to preserve haemodialysis access. If hae-
modialysis is delivered through a central vascular catheter, this access should be 
preserved for this purpose alone and additional central access obtained as needed. 
If the peritoneum is breached in a peritoneal dialysis patient, alternative access for 
dialysis needs to be considered as peritoneal dialysis is less likely to be successful.
Depending on the immunological risk of the patient, in the presence of DGF, a 
reduction in target tacrolimus levels can be contemplated. Many transplant centres 
target a tacrolimus level 8–10 μg/L in the peri-transplantation period. Provided the 
patient is not considered high immunological risk, reduction of the target range could 
be considered. The use of thymoglobulin in the setting of DGF is controversial in the 
absence of immunological risk factors advocating its use as an induction agent [15].
Risk factor Relative impact
Donation after circulatory 
death
2× higher rate of ATN. No difference in outcome at 1 year
Donor on inotropes Early function 58% (vs. 83%). 1-year survival 73% (vs. 91%)
Cold ischemia time 23% increase risk of DGF for every 6 h
Donor age > 55y 2× higher rate of DGF
Other donor factors Poor reperfusion, death from stroke, presence of AKI associated with 
increased risk
Higher PRA% Associated higher risk of requiring dialysis post-transplant
Recipient hypovolaemia Lower pre-operative DBP, intra-operative albumin requirement and pre-
operative haemodialysis with UF
Dialysis modality Higher rate of DGF in haemodialysis vs. peritoneal dialysis
Special circumstances Thrombophilia, previous transplant
Adapted from Perico et al. [75].
Table 8. 
Risk factors for delayed graft function.
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5.5 Renal vascular complication
In transplant recipients who have established a good urine output post-oper-
atively, the sudden development of oliguria or anuria should prompt a review of 
urinary catheter patency as well as raise the possibility of transplant vessel pathol-
ogy. Early vascular pathology may be caused by structural or anatomical factors 
such as vessel kinking, anatomically disadvantageous configurations putting 
traction on the recipient vessels or thrombosis. Distinguishing between the vari-
ous pathologies can be challenging clinically, with reliance on duplex ultrasound 
imaging and knowledge of donor vascular pathology through collaboration with 
transplant surgeons.
Renal transplant artery or vein thrombosis is a serious, although fortunately 
uncommon peri-transplant complication, with an incidence of 2–3%, classically 
occurring in the first week post-transplant [77]. Clinical features of transplant 
artery thrombosis are typically limited to the sudden onset of oligoanuria, while 
transplant vein thrombosis may cause allograft swelling, pain and frank haema-
turia in addition. Predisposing risk factors are decreased perfusion pressures and 
hypotension as well as donor factors—difficult bench surgery, multiple vessels, 
prolonged cold ischaemia time and vessel atherosclerosis [77, 88]. Rarer recipi-
ent risk factors, when present, can dramatically increase the risk of thrombosis, 
including in the transplant vessels. Recipients with thrombophilia, notably factor V 
Leiden mutation or anti-phospholipid antibodies, have been associated with higher 
risk (2.87 increased risk in one study) of adverse graft outcomes [89, 90]. Diagnosis 
of transplant vessel pathology may be obtained by urgent renal duplex ultrasonog-
raphy; however, the abrupt onset of anuria in the early post-operative period is an 
indication for urgent surgical review and consideration of surgical re-exploration, 
due to the very short window after transplant arterial thrombosis before irretriev-
able graft loss occurs.
Renal transplant artery stenosis tends to be a later complication but can 
occasionally manifest in the perioperative period. The classical clinical features 
associated with stenosis of the transplant artery are hypertension, allograft 
dysfunction and fluid overload due to salt and water retention. Risk factors for 
early transplant artery stenosis tend to be donor related with atherosclerotic 
vessels or difficult bench surgery [77]. An association with acute rejection has 
also been described [91]. Diagnosis is by duplex scan showing increased veloc-
ity across the anastomotic sites and a flow differential between the aorta and 
transplant artery.
Intermittent vessel kinking caused by allograft nephroptosis can be diagnosti-
cally challenging due to the positional nature of the pathology [92]. Duplex scans 
may be non-diagnostic, and performing imaging in a non-prone position may assist 
in the diagnosis of positional vessel compression or kinking, and CT angiography 
may provide additional diagnostic information in this situation.
5.6 Renal ureteric complications
Ureteric pathology is more common than vascular pathology, but rarely affects 
graft survival [93]. The most common early urological complication is a urine leak 
with an estimated incidence of 8%, followed by ureteric stenoses with a similar 
incidence occurring later in the transplant course [77, 94]. Other complications of 
vesicoureteric reflux and urolithiasis are uncommon [95].
Ureteric leaks, like vascular pathology, typically occur in first few weeks 
post-transplant and may present with localised pain or swelling at the site of the 
allograft, increased surgical drain output or a peri-transplant collection seen on 
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imaging [95]. Non-technical risk factors include recipient agent, pre-transplant 
urological pathology, immunosuppressive regimen and donor factors [94].
When there is a clinical suspicion for a urine leak due to increased surgical drain 
output, or if a peri-transplant collection is drained, the fluid should be sent for cre-
atinine concentration analysis to differentiate serous or lymphatic fluid (which will 
have a similar creatinine concentration to the blood) from urine. Following drain 
removal, recipients with a urine leak may complain of pain due to fluid accumula-
tion or if there is a significant urine leak, graft function will appear to deteriorate 
due to reabsorption of urinary creatinine and urea.
The management of urine leaks can be complex and often requires liaison with a 
transplant urologist. It may be possible to manage minor urine leaks conservatively 
via bladder decompression with an indwelling catheter in addition to ureteric 
stenting to allow the distal anastomosis to heal. Larger leaks may require further 
investigation in contrast to enhanced computer tomography, insertion of a percuta-
neous nephrostomy or surgical repair [95]. A more detailed discussion of this topic 
is beyond the scope of this chapter.
5.7 Infection
As a consequence of induction immunosuppression, transplant patients are 
particularly prone to infection in the perioperative phase. However, sepsis can be 
challenging to diagnose during this period because immunocompromised patients 
may not manifest the typical features of a systemic inflammatory response. Due to 
steroid therapy, most patients will exhibit a peripheral neutrophilia. In general, any 
change in physiological parameters, clinical deterioration or a temperature > 37.5°C 
should prompt consideration of sepsis, and a sepsis screen should be requested 
including [96]:
• haematology panel
• C-reactive protein
• blood culture and venous lactate
• urinalysis and urine culture
• chest X-ray
• additional testing as appropriate—respiratory virus screen, lumbar puncture, 
opportunistic infection screen
• empiric antibiotic therapy within 1 h of suspected sepsis diagnosis
Although transplant recipients are susceptible to opportunistic pathogens such as 
CMV, EBV, mycobacteria, Pneumocystis jiroveci and fungi, these are unusual in the early 
post-transplant period. Infections occurring soon after transplantation are frequently 
nosocomial, associated with hospitalisation, intravenous and urinary catheters and 
intubation during surgery. In some instances, infection may be donor derived [97].
5.7.1 Bacterial infection
Urinary tract infections (UTI) are the most common cause of bacterial infec-
tion requiring hospitalisation in transplant patients, followed by pneumonia, 
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surgical site infections and septicaemia [98]. Retrospective database studies have 
estimated a cumulative incidence of 17% in the first 6 months post-transplant, 
which rises to 60% for women and 47% for men at 3 years [99]. The presentation 
for UTI is similar to that of the general population and management identical 
to complicated UTIs with 7–14 days of antibiotic therapy, although the optimal 
duration has not been well established [98]. Management of post-transplant 
candiduria is controversial, without definite improvement in clinical outcomes 
following therapy [100]. Other bacterial pathologies are treated in the same way 
as in the general population with anticipated more frequent and longer duration 
antibiotic use due to physician concern over immunosuppressed state and propen-
sity for more severe infection.
5.8 Rejection
In the early era of transplantation, hyperacute rejection due to the presence 
of preformed donor-specific antibodies (DSAs) occurring in the first minutes or 
hours after perfusion of the transplant was a significant risk. However, with the 
introduction of the complement-dependent cytotoxic cross-match, as described 
by Patel and Terasaki [101], and more recently solid phase assays that are able to 
detect DSAs with high sensitivity, hyperacute rejection is now extremely rare [102]. 
Nevertheless, early acute rejection remains a common occurrence, with a reported 
incidence of 7–25% depending on the level of immunological risk and choice of 
induction immunosuppression [21, 103–106]. Contemporary rejection rates in 
Australia and New Zealand are shown in Table 9.
In the perioperative period, DGF persisting beyond 4–5 days, decreasing urine 
output or an unexplained rise in creatinine by >15–20%, should prompt consider-
ation of rejection as the underlying cause (Section 5.4). Unless there is a contrain-
dication such as active bleeding or an unavoidable requirement for anticoagulation, 
the diagnosis requires a renal biopsy, both to exclude alternative causes of graft 
dysfunction and to characterise the histological pattern and severity of rejection. 
Rejection is classified histologically using the Banff criteria into borderline rejec-
tion, cell-mediated rejection, antibody-mediated rejection and mixed rejection 
[107, 108]. Treatment of cellular rejection would usually involve pulsed methyl-
prednisolone 0.25–1.0 g daily for 3 days as first-line treatment, combined with a 
T-cell depleting therapy such as thymoglobulin/ATG if the rejection is histologically 
severe rejection (Banff class 2 or greater), or if there is a suboptimal response 
to methylprednisolone [109]. The optimal therapy for acute antibody-mediated 
rejection remains unclear, but would typically include pulsed methylprednisolone, 
plasma exchange (often combined with intravenous immunoglobulin at a dose of 
0.1 g/kg following each exchange) outcomes [110–112]. Some centres also advocate 
the use of a B cell depleting antibody such as rituximab or the proteasome inhibi-
tor bortezomib, although currently there is no strong evidence that these agents 
improve clinical outcomes [111, 113–115].
First allograft (%) Second or subsequent allograft (%)
Living donor 17.4 16.7
Deceased donor 15.2 18.6
Data from ANZDATA Registry. 41st Report, Chapter 7: Kidney Transplantation. Australia and New Zealand Dialysis 
and Transplant Registry, Adelaide, Australia. 2018. http://www.anzdata.org.au.
Table 9. 
Acute rejection rates in the first six months post-transplant.
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6. Conclusions
Kidney transplantation has evolved from a highly experimental therapy to 
become recognised as the gold standard treatment for many patients with ESKD 
[116]. This progress has occurred through the many iterative developments in the 
surgical and medical management of transplant recipients, not the least of which 
being the introduction of highly effective immunosuppressive agents. Delivering 
high standards of clinical care during the perioperative period is a crucial step in 
achieving excellent allograft outcomes. This chapter provides an overview of the 
approach to assessing potential recipients admitted for transplantation, and guid-
ance on typical perioperative medication and fluid prescriptions, as well as post-
operative monitoring and early complications.
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